Skip to main content
AN

Anaveon

Bottmingen, Switzerland
Last funding
$119.7M
Series BDec 2021

Anaveon is a developing IL-2 complexes which selectively promote effector T cell functions.

Backed byForbion Capital PartnersPfizer Venture InvestmentsCowen Healthcare InvestmentsPontifaxNovartis Venture Fund

About Anaveon

How much funding has Anaveon raised?

Anaveon has raised $119.7M in total funding. The most recent round was Series B. The last funding was announced in December 2021.

Who are Anaveon's investors?

Anaveon's investors include Forbion Capital Partners, Pfizer Venture Investments, Cowen Healthcare Investments, Pontifax, Novartis Venture Fund.

Where is Anaveon headquartered?

Anaveon is headquartered in Bottmingen, Switzerland.

What does Anaveon do?

Anaveon is a developing IL-2 complexes which selectively promote effector T cell functions.

What stage is Anaveon at?

Anaveon is at the Series B stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .

MLA
"Anaveon — Funding & Investors." VCBacked, December 16, 2021, https://www.vcbacked.co/company/anaveon. Accessed November 17, 2026.
APA
VCBacked. (2021). Anaveon — Funding & Investors. Retrieved November 17, 2026, from https://www.vcbacked.co/company/anaveon
Wikipedia (cite web)
{{cite web |title=Anaveon — Funding & Investors |url=https://www.vcbacked.co/company/anaveon |website=VCBacked |access-date=November 17, 2026}}

Profile data sourced and verified per the VCbacked methodology · Last funding round dated

Work at Anaveon? Request a listing update